![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer
We have previously demonstrated S-1 is non-inferior to taxane with respect to overall survival as first-line chemotherapy for HER2-negative metastatic breast cancer. We aimed to confirm whether S-1 is also non...
-
Article
Open AccessKi-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study
The effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, has not been evaluated.
-
Article
Open AccessIntegrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer
Fusion genes are good candidates of molecular targets for cancer therapy. However, there is insufficient research on the clinical implications and functional characteristics of fusion genes in colorectal cance...